Anish Patel

Anish Patel

Auto-generated profile, based on publicly available information

Anish Patel

Department of Medicine, Division of Gastroenterology & Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
APAnish Patel
Anish Patel
HPHinaben Panchal
Hinaben Panchal
MDMarla C. Dubinsky
Marla C. Dubinsky
Mucosal healing as measured by endoscopic activity is the therapeutic target for ulcerative colitis (UC) and associated with improved outcomes. We investigated the clinical utility of fecal calprotectin (FC) levels to predict depth of remission, including histological remission in patients with UC. We performed a retrospective chart review of patients with UC who underwent a full colonoscopy and FC measured within 6 weeks before colonoscopy at a tertiary inflammatory bowel disease center. Clinical, endoscopic, and histological disease activity was assessed by Patient Reported Outcomes (PRO2), Mayo endoscopic score (0–3), and Nancy score (0–4), respectively. Outcomes of interest included (1) deep remission (PRO2 remission and Mayo score 0) and (2) deeper remission (deep remission plus Nancy score 0/1). Mann–Whitney U and Kruskal–Wallis tests and area under the curve–receiver operating characteristic curve analysis were used to evaluate accuracy of the predictive values. In 68 patients, increasing FC levels were significantly associated with disease extent (P = 0.006), Mayo score (P = 0.001), and Nancy scores (P < 0.001). Patients with Mayo score 0/1 and Nancy score ≤1 (n = 20) had significantly lower FC levels compared with Mayo 0/1 and Nancy ≥ 2 (31 versus 231; P < 0.001). FC level of ≤60 μg/g predicted deep remission (area under the curve = 0.92, sensitivity 86%, and specificity 87%) and deeper remission (area under the curve = 0.91, sensitivity 83%, and specificity 90%). FC levels significantly correlated with endoscopic extent, mucosal healing, and histological activity, and reflect microscopic disease activity even in the face of macroscopic healing. An FC level of ≤60 μg/g robustly predicted depth of remission, suggesting that FC can be used instead of colonoscopy in a treat-to-target paradigm in patients with UC.

26 January 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JBJeffrey A. Berinstein
Jeffrey A. Berinstein
TKTaylor Karl
Taylor Karl
APAnish Patel
Anish Patel
MDMichael Dolinger
Michael Dolinger
TBTerrence A. Barrett
Terrence A. Barrett
PHPeter D.R. Higgins
Peter D.R. Higgins
INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

1 November 2009 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
APAnish A. Patel
Anish A. Patel
DTDawn M. Torres
Dawn M. Torres
SHStephen A. Harrison
Stephen A. Harrison
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common causes of liver disease worldwide and has grown proportionately with the rise in obesity. The prevalence of NAFLD is now thought to be around 20% to 40% of the entire population in industrialized Western countries. Insulin resistance, a product of obesity, is central to the pathogenesis of NAFLD, and is improved with weight loss, making this modality the primary goal of therapy. A combination of dietary modifications and increased physical activity, although hard to maintain, is thought to have significant long-term benefits, although further study is required to determine the best and most effective approaches to lifestyle modification. Alternatively, for those individuals who are unable to lose weight despite aggressive efforts, bariatric surgery, which has been shown rather convincingly to improve underlying fatty liver disease, may offer a solution. This review discusses dietary modification, exercise, weight loss pharmacotherapy, and surgical intervention as potential options for patients with NAFLD.


1 December 2014 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
APAnish Patel
Anish Patel
RPRahul Pathak
Rahul Pathak
VDVrushak Deshpande
Vrushak Deshpande
SPSunil Patel
Sunil Patel
PWPrasanna Wickremesinghe
Prasanna Wickremesinghe
DVDeepak Vadada
Deepak Vadada
Radiation proctopathy is a complication of pelvic radiotherapy, which occurs in patients treated for carcinoma of the prostate, rectum, urinary bladder, cervix, uterus, and testes. If it presents within 6 weeks to 9 months after therapy, it is called acute radiation proctitis/proctopathy (ARP), and if it occurs 9 months to a year after treatment, it is classified as chronic radiation proctitis/proctopathy (CRP). CRP occurs in 5%–20% of patients receiving pelvic radiation, depending on the radiation dose and the presence or absence of chemotherapy. In many cases, CRP resolves spontaneously, but in some, it can lead to persistent rectal bleeding. Other symptoms of CRP include diarrhea, mucoid discharge, urgency, tenesmus, rectal pain, and fecal incontinence. Despite the availability of several therapies, many patients fail to respond, and continue to suffer in their quality of life. Radiofrequency ablation (RFA) is a newer endoscopic technique that uses radiofrequency energy to ablate tissue. This is an emerging way to treat radiation proctopathy and other mucosal telangiectasia. We present three cases of radiation proctopathy treated with RFA at our institute and review the literature on treatment modalities for CRP. We were also able to find 16 other cases of CRP that used RFA, and review their literature as well as literature on other treatment modalities.

1 January 2014 in Journal of Gastroenterology and Hepatology Research
Verified
Journal Article
Open access
PDF file
APAnish Patel
Anish Patel
SSSeth Sclair
Seth Sclair
OJOmer Junaidi
Omer Junaidi
VCViolet Copado
Violet Copado
CLCynthia Levy
Cynthia Levy
KBKalyan R Bhamidimarri
Kalyan R Bhamidimarri
Response Guided Treatment with Telaprevir or Boceprevir in End Stage Renal Disease Patients with Hepatitis C Genotype 1